Tarsus Pharmaceuticals, Inc.

TARS

Tarsus Pharmaceuticals, Inc.

TARS

Insider Sentiment (TTM):

Last Purchase:2023-12-15Last Sale:2026-06-17Shares Purchased (TTM):0Shares Sold (TTM):172,335

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:43,872,859Shares Outstanding:42,956,973Institutional Ownership Pct.:102.13%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents Fair Value Disclosure	205	102	184	113	97	176	95	176	181	194	225	227
Restricted Cash Current	0	0	1	-	-	-	0	-	-	-	-	-
Marketable Securities Current	245	287	234	289	284	232	197	141	142	105	2	20
Accounts Receivable Net Current	96	100	85	73	58	62	47	29	30	30	17	5
Inventory Net	4	5	4	4	4	3	3	3	2	4	3	0
Other Receivables Net Current	2	17	2	2	2	2	1	1	1	1	1	1
Prepaid Expense Current	10	27	13	22	29	6	15	7	6	7	8	6
Assets Current	562	537	523	502	474	481	357	357	363	341	256	259
Restricted Cash Noncurrent	2	2	2	3	3	3	3	-	-	-	0	-
Inventory Noncurrent	3	3	3	3	3	3	3	3	3	-	0	-
Property Plant And Equipment Net	20	18	12	6	3	3	2	2	2	1	1	2
Intangible Assets Net Excluding Goodwill	7	7	7	8	8	8	8	9	4	4	4	4
Operating Lease Right Of Use Asset	10	10	10	10	0	0	1	2	2	2	2	2
Long Term Investments	7	4	4	3	3	3	3	3	3	0	1	0
Other Assets Noncurrent	1	1	2	1	1	1	1	1	1	1	2	1
Assets	611	581	562	535	495	501	377	376	377	349	265	268
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	40	24	16	-	-	-	9	-	-	-	-	-
Employee Related Liabilities Current	12	9	18	14	12	10	16	11	8	6	13	8
Accounts Payable And Other Accrued Liabilities Cur…	124	111	102	103	79	76	55	55	44	37	24	15
Liabilities Current	176	144	136	117	90	86	81	66	52	43	37	23
Long Term Debt Noncurrent	73	73	72	72	72	72	72	72	72	30	30	30
Other Liabilities Noncurrent	16	16	11	10	-	-	0	1	1	2	2	2
Liabilities	264	232	219	199	162	158	152	139	125	74	69	55
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	799	783	770	753	738	728	585	574	566	556	442	416
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	0	0	0	0	0	0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-452	-434	-427	-418	-406	-385	-360	-337	-314	-280	-245	-203
Stockholders Equity	347	349	343	335	333	342	225	237	252	275	197	214
Liabilities And Stockholders Equity	611	581	562	535	495	501	377	376	377	349	265	268
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	43	43	43	42	42	42	38	38	38	38	34	33
Shares Outstanding	43	43	43	42	42	42	38	38	38	38	34	33

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-8.28%	-2.84%	-9.42%	-	-	-	-	-	-	-	-	-
2025	-14.55%	-19.18%	-14.02%	40.68%	35.18%	58.65%	11.83%	14.38%	-4.39%	-7.30%	-3.38%	-10.22%
2024	-11.75%	-27.23%	-33.04%	14.82%	37.70%	66.92%	11.36%	19.71%	15.60%	21.02%	19.28%	5.84%
2023	-	-	-	-2.06%	4.47%	-19.11%	1.86%	30.06%	65.70%	-14.30%	-17.29%	-2.50%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.20	3.74	3.85	4.29	5.26	5.57	4.42	5.42	7.03	8.01	6.93	11.15
Quick Ratio	3.12	3.53	3.72	4.07	4.89	5.47	4.21	5.27	6.87	7.76	6.64	10.89
Working Capital	386.24M	393.72M	387.09M	384.65M	384.18M	394.47M	276.09M	291.25M	311.02M	298.20M	219.20M	236.03M
Leverage & Debt
Debt to Equity	0.76	0.67	0.64	0.60	0.49	0.46	0.68	0.58	0.49	0.27	0.35	0.26
Interest Coverage TTM	-5.54	-5.74	-7.94	-9.68	-10.65	-12.02	-15.36	-21.54	-31.66	-42.77	-42.78	-37.14
Debt Ratio	0.43	0.40	0.39	0.37	0.33	0.32	0.40	0.37	0.33	0.21	0.26	0.20
Efficiency & Turnover
Asset Turnover TTM	1.10	0.99	0.96	0.80	0.68	0.55	0.57	0.40	0.29	0.15	0.07	0.06
Days Sales Outstanding TTM	46.46	55.52	53.30	50.74	54.26	72.10	63.22	48.60	129.27	138.87	347.72	68.31
Receivables Turnover TTM	7.86	6.57	6.85	7.19	6.73	5.06	5.77	7.51	2.82	2.63	1.05	5.34
Per Share Metrics
Diluted EPS TTM	-1.07	-1.12	-1.59	-1.90	-2.17	-2.67	-3.07	-3.50	-3.97	-4.20	-4.62	-3.51
Free Cash Flow Per Share TTM	1.42	-0.73	-0.53	-0.85	-1.45	-1.73	-2.25	-2.65	-3.32	-3.81	-4.05	-2.96
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	93.28%	93.48%	93.20%	93.26%	93.36%	92.99%	92.99%	92.97%	92.50%	-	-	-
Operating Profit Margin TTM	-8.00%	-9.50%	-15.72%	-23.88%	-33.18%	-46.72%	-65.90%	-108.47%	-187.55%	-366.27%	-820.53%	-791.66%
Net Profit Margin TTM	-7.67%	-9.02%	-14.72%	-22.17%	-31.13%	-44.91%	-63.16%	-103.64%	-180.00%	-348.22%	-778.89%	-748.66%
Growth Metrics
Net Revenue Growth (1Y)	105.17%	128.99%	146.71%	182.44%	254.45%	449.03%	948.62%	801.96%	566.99%	53.22%	-32.42%	-11.04%
Net Income Growth (1Y)	-49.48%	-54.01%	-42.52%	-39.59%	-38.70%	-29.19%	-14.97%	24.87%	65.00%	127.06%	118.86%	69.85%
EPS Growth (1Y)	-50.68%	-57.88%	-48.27%	-45.58%	-45.27%	-36.47%	-33.56%	-0.38%	16.98%	72.01%	83.38%	47.89%
Valuation Metrics
P/E TTM	-58.77	-62.44	-51.51	-31.20	-18.65	-19.26	-18.02	-9.40	-6.85	-8.66	-4.38	-5.06
P/B TTM	7.88	8.64	9.96	7.56	5.16	5.90	9.27	5.32	4.08	4.66	3.02	2.55
P/S TTM	4.50	5.63	7.58	6.92	5.81	8.65	11.38	9.74	12.33	30.15	34.10	37.87
Market Cap	2.73B	3.01B	3.42B	2.53B	1.72B	2.02B	2.08B	1.26B	1.03B	1.28B	595.01M	544.16M
Enterprise Value	2.60B	2.98B	3.31B	2.49B	1.69B	1.91B	2.06B	1.16B	918.52M	1.12B	399.88M	347.20M
Calculated Values
Free Cash Flow TTM	61.73M	-31.54M	-22.31M	-36.30M	-61.58M	-67.87M	-84.59M	-101.68M	-125.48M	-134.65M	-119.00M	-90.66M
Net Debt	-133.83M	-31.60M	-113.77M	-43.01M	-27.08M	-106.37M	-25.54M	-104.50M	-109.52M	-163.77M	-195.13M	-196.96M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-17Sale

Owner: Azamian, Bobak R.

Title: President/CEO and Board Chair

Shares: 10,000

Price/Share: $61.53

Value: $615,300.00

Shares Owned: 847,991

Relationship: Director,Officer

Ownership: Indirect

2026-06-16Sale

Owner: Farrow, Jeffrey S

Title: See Remarks

Shares: 14,396

Price/Share: $60.95

Value: $877,436.20

Shares Owned: 56,801

Relationship: Officer

Ownership: Direct

2026-06-15Sale

Owner: Link, William J Phd

Title: -

Shares: 12,500

Price/Share: $62.46

Value: $780,750.00

Shares Owned: 106,786

Relationship: Director

Ownership: Direct

2026-06-15Sale

Owner: Goodrich, Katherine

Title: -

Shares: 2,954

Price/Share: $62.08

Value: $183,384.32

Shares Owned: 2,233

Relationship: Director

Ownership: Direct

2026-03-20Sale

Owner: Neervannan, Seshadri

Title: Chief Operating Officer

Shares: 2,989

Price/Share: $66.75

Value: $199,515.75

Shares Owned: 82,791

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-17	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	10,000	61.53	$615,300.00	847,991	4
2026-06-16	Farrow, Jeffrey S	Officer	See Remarks	Direct	Sale	14,396	60.95	$877,436.20	56,801	4
2026-06-15	Link, William J Phd	Director	-	Direct	Sale	12,500	62.46	$780,750.00	106,786	4
2026-06-15	Goodrich, Katherine	Director	-	Direct	Sale	2,954	62.08	$183,384.32	2,233	4
2026-03-20	Neervannan, Seshadri	Officer	Chief Operating Officer	Direct	Sale	2,989	66.75	$199,515.75	82,791	4
2026-03-19	Farrow, Jeffrey S	Officer	See Remarks	Direct	Sale	2,186	67.00	$146,462.00	43,316	4
2026-03-19	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Direct	Sale	11,964	67.00	$801,588.00	33,421	4
2026-03-19	Neervannan, Seshadri	Officer	Chief Operating Officer	Direct	Sale	4,589	67.00	$307,463.00	85,780	4
2026-03-19	Whitfield, Dianne C.	Officer	Chief Human Resources Officer	Direct	Sale	4,174	67.00	$279,658.00	35,028	4
2026-03-19	Mottiwala, Aziz	Officer	Chief Commercial Officer	Direct	Sale	4,440	67.00	$297,480.00	61,480	4
2026-03-19	Wahl, Bryan	Officer	General Counsel	Direct	Sale	4,231	67.00	$283,477.00	63,959	4
2026-03-19	Lin, Elizabeth Yeu	Officer	Chief Medical Officer	Direct	Sale	390	67.00	$26,130.00	23,308	4
2026-03-16	Link, William J Phd	Director	-	Direct	Sale	12,500	68.96	$862,000.00	116,332	4
2026-03-04	Neervannan, Seshadri	Officer	Chief Operating Officer	Direct	Sale	8,366	76.67	$641,421.22	70,817	4
2026-01-02	Whitfield, Dianne C.	Officer	Chief Human Resources Officer	Direct	Sale	15,565	81.41	$1,267,146.65	23,393	4
2025-12-24	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	6,000	82.98	$497,880.00	857,991	4
2025-12-16	Whitfield, Dianne C.	Officer	Chief Human Resources Officer	Direct	Sale	7,397	80.10	$592,499.70	38,958	4
2025-12-16	Lin, Elizabeth Yeu	Officer	Chief Medical Officer	Direct	Sale	2,078	79.50	$165,201.00	21,941	4
2025-12-15	Link, William J Phd	Director	-	Direct	Sale	12,500	81.65	$1,020,625.00	128,832	4
2025-09-24	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	6,000	55.37	$332,220.00	812,106	4
2025-09-08	Link, William J Phd	Director	-	Direct	Sale	27,116	57.00	$1,545,612.00	143,332	4
2025-08-11	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	6,000	50.00	$300,000.00	818,106	4
2025-06-17	Farrow, Jeffrey S	Officer	See Remarks	Direct	Sale	13,608	40.42	$550,035.36	36,704	4
2025-06-16	Lin, Elizabeth Yeu	Officer	Chief Medical Officer	Direct	Sale	1,006	41.08	$41,326.48	7,694	4
2025-06-09	Mottiwala, Aziz	Officer	Chief Commercial Officer	Direct	Sale	17,500	43.76	$765,800.00	47,557	4
2025-03-24	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	6,000	50.00	$300,000.00	824,106	4
2025-03-20	Neervannan, Seshadri	Officer	Chief Operating Officer	Direct	Sale	2,435	50.11	$122,017.85	79,682	4
2025-03-20	Wahl, Bryan	Officer	General Counsel	Direct	Sale	3,084	50.11	$154,539.24	51,712	4
2025-03-20	Whitfield, Dianne C.	Officer	Chief Human Resources Officer	Direct	Sale	2,137	50.11	$107,085.07	46,355	4
2025-03-20	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Direct	Sale	8,534	50.11	$427,638.74	53,635	4
2025-03-20	Mottiwala, Aziz	Officer	Chief Commercial Officer	Direct	Sale	3,365	50.11	$168,620.15	65,057	4
2025-03-20	Farrow, Jeffrey S	Officer	See Remarks	Direct	Sale	1,186	50.11	$59,430.46	22,431	4
2024-08-12	Link, William J Phd	Director	-	Indirect	Sale	35,000	26.27	$919,450.00	0	4
2024-06-18	Farrow, Jeffrey S	Officer	See Remarks	Direct	Sale	10,445	27.47	$286,924.15	18,136	4
2024-03-18	Mottiwala, Aziz	Officer	Chief Commercial Officer	Direct	Sale	4,766	30.60	$145,839.60	54,075	4
2024-03-18	Wahl, Bryan	Officer	General Counsel	Direct	Sale	4,436	30.60	$135,741.60	40,951	4
2024-03-18	Whitfield, Dianne C.	Officer	Chief Human Resources Officer	Direct	Sale	4,314	30.60	$132,008.40	34,181	4
2024-03-18	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Direct	Sale	10,415	30.60	$318,699.00	26,456	4
2024-03-18	Neervannan, Seshadri	Officer	Chief Operating Officer	Direct	Sale	4,879	30.60	$149,297.40	64,767	4
2023-12-27	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	8,000	20.22	$161,760.00	830,106	4
2023-12-20	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	40,000	20.16	$806,400.00	838,106	4
2023-12-20	Trevejo, Jose M.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,252	20.00	$45,040.00	2,251	4
2023-12-15	Goldberg, Andrew D.	Director	-	Direct	Purchase	1,000	18.96	$18,960.00	3,000	4
2023-11-30	Whitfield, Dianne C.	Officer	Chief Human Resources Officer	Direct	Sale	8,355	16.31	$136,270.05	26,784	4
2023-11-30	Wahl, Bryan	Officer	General Counsel	Direct	Sale	8,356	16.31	$136,286.36	31,966	4
2023-11-15	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	8,000	18.61	$148,880.00	878,106	4
2023-10-18	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	8,000	13.24	$105,920.00	886,106	4
2023-10-05	Trevejo, Jose M.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,604	18.00	$28,872.00	4,503	4
2023-09-20	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	8,000	17.21	$137,680.00	894,106	4
2023-08-23	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	8,000	17.23	$137,840.00	902,106	4
2023-08-15	Lin, Elizabeth Yeu	Director	-	Indirect	Purchase	9,506	16.80	$159,700.80	15,866	4
2023-07-19	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	103,900	19.66	$2,042,674.00	910,106	4
2023-07-19	Mottiwala, Aziz	Officer	Chief Commercial Officer	Direct	Sale	2,400	20.05	$48,120.00	45,806	4
2023-07-12	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	9,000	17.35	$156,150.00	1,014,006	4
2023-06-21	Azamian, Bobak R.	Director,Officer	President/CEO and Board Chair	Indirect	Sale	8,000	18.63	$149,040.00	1,023,006	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

102.13%

Inst. Shares: 43,872,859

Shares Outstanding: 42,956,973

2025-12-31

102.47%

Inst. Shares: 42,814,620

Shares Outstanding: 41,784,014

2025-09-30

101.67%

Inst. Shares: 43,320,775

Shares Outstanding: 42,607,717

2025-06-30

104.78%

Inst. Shares: 44,385,276

Shares Outstanding: 42,360,452

2025-03-31

105.65%

Inst. Shares: 41,570,288

Shares Outstanding: 39,345,359

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	43,872,859	42,956,973	102.13%
2025-12-31	42,814,620	41,784,014	102.47%
2025-09-30	43,320,775	42,607,717	101.67%
2025-06-30	44,385,276	42,360,452	104.78%
2025-03-31	41,570,288	39,345,359	105.65%
2024-12-31	38,162,149	37,604,538	101.48%
2024-09-30	41,432,754	38,381,968	107.95%
2024-06-30	38,479,980	37,823,233	101.74%
2024-03-31	38,132,258	35,300,655	108.02%
2023-12-31	29,824,734	29,383,276	101.50%
2023-09-30	29,103,595	30,622,440	95.04%
2023-06-30	20,973,511	26,815,733	78.21%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Tarsus Pharmaceuticals, Inc. (TARS) — SEC Financial Statements & Analysis

Tarsus Pharmaceuticals, Inc. (TARS) is a biological products, (no diagnostic substances) company, incorporated in DE. Tarsus Pharmaceuticals, Inc. trades on Nasdaq as: TARS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Tarsus Pharmaceuticals, Inc. reported a 105.17% year-over-year revenue growth, a Gross Profit Margin of 93.28% (TTM), a Debt-to-Equity ratio of 0.76x, a Price-to-Sales (P/S) ratio of 4.50x (TTM), a Price-to-Book (P/B) ratio of 7.88x (TTM), at a market cap of $2.73B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 105.17%
Gross Profit Margin TTM: 93.28%
Debt To Equity: 0.76x
P/S TTM: 4.50x
P/B TTM: 7.88x
Market Cap: $2.73B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Tarsus Pharmaceuticals, Inc. in?

Tarsus Pharmaceuticals, Inc. (TARS) operates in the Biological Products, (No Diagnostic Substances) industry.

What is TARS's market cap?

Tarsus Pharmaceuticals, Inc. (TARS) has a market capitalization of $2.73B as of 2026-06-30.

What exchange does TARS trade on?

Tarsus Pharmaceuticals, Inc. (TARS) trades on the Nasdaq.

Where is Tarsus Pharmaceuticals, Inc. incorporated?

Tarsus Pharmaceuticals, Inc. is incorporated in DE.